BLUEPRINT—A BLUEPRINT of Haematopoietic Epigenomes


At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • No disease focus
  • Location: Europe

Abstract

BLUEPRINT, a new large-scale research project, will lead to targeted diagnostics, new treatments, and preventive measures for specific diseases in individual patients—an approach known as personalized medicine. BLUEPRINT is the European cornerstone of an international research cooperation effort—the International Human Epigenome Consortium (IHEC)—bringing together organizations and researchers from across the globe.

Mission

The BLUEPRINT consortium has been formed to further the understanding of how genes are activated or repressed in both healthy and diseased human cells. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukemic counterparts. It aims to generate at least 100 reference epigenomes and study them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. This aim feeds into IHEC’s overall objective. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by IHEC.
 
This resource-generating activity will be complemented by hypothesis-driven research into blood-based diseases, including common leukemias and autoimmune disease (Type 1 diabetes), by discovery and validation of epigenetic markers for diagnostic use and by epigenetic target identification. Because epigenetic changes are reversible, they can be targets for the development of novel and more individualized medical treatments.
 
The involvement of innovative companies will energize epigenomic research in the private sector by the development of smart technologies for better diagnostic tests and by the identification of new targets for compounds. Thus the results of the BLUEPRINT project may lead to targeted diagnostics, new treatments, and preventive measures for specific diseases in individual patients—an approach known as personalized medicine.

Consortium History

October 1, 2011: The BLUEPRINT consortium was launched.

Financing

The European Commission’s Seventh Framework Programme is funding €29 million of the total €39 million project cost.

Data Sharing

The Blueprint Data Access Committee will consider applications for access to data sets stored in the European Genome-phenome Archive (EGA) when authorized to do so by the BLUEPRINT consortium and the holders of the original consent documents. Access to data will be granted to qualified researchers for appropriate use. A qualified researcher refers to a scientist who is employed, or a student enrolled at, or legitimately affiliated with, an academic, nonprofit, or government institution, or a commercial company.

Access to data will be granted to researchers for appropriate use and will be governed by the provisions laid out in the associated informed consent for each cohort or collection and by the terms contained in the Data Access Agreement.

The Blueprint Data Access Committee is concerned only with access to the data stored within the EGA from the Blueprint Consortium. Access is conditional upon availability of samples and/or data and signed agreement by the researcher(s) and the responsible employing institution to abide by policies related to publication, data disposal, ethical approval, and confidentiality.

Points of Contact

Marion Bussemakers, PhD
BLUEPRINT Project Manager
NCMLS/Radboud University
274 Dept. Molecular Biology
PO Box 9101
6500 HB Nijmegen
The Netherlands
phone: +31-24-3615157
fax: +31 24 3610520

Sponsors & Partners

Academisch Ziekenhuis Groningen

Barcelona Supercomputing Center

Cellzome AG

Centre National de la Recherche Scientifique

Christian-Albrechts-Universitaet Zu Kiel

Consorci Institut D’Investigacions Biomediques August Pi I Sunyer

Diagenode SA

Erasmus Universitair Medisch Centrum Rotterdam

European Molecular Biology Laboratory

European Research and Project Office GMBH

Fundacio Privada Centre de Regulacio Genomica

Fundacio Privada Institut D’Investigacio Biomedica de Bellvitge

Fundacio Privada Parc Cientific de Barcelona

Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III

Genomatix Software GMBH

Genome Research Limited

Halo Genomics AB

Institut National de la Sante et de la Recherche Medicale (Inserm)

Istituto Europeo di Oncologia SRL

Københavns Universitet

Lunds Universitet

Max Planck

Novartis Forschungsstiftung

Oxford Nanopore Technologies Ltd

Queen Mary And Westfield College, University of London

Radboud University

Seconda Università Degli Studi di Napoli

Siena Biotech Spa

Sigolis AB

The Babraham Institute

The Chancellor, Masters and Scholars of the University of Cambridge

The University of Edinburgh

Universita Degli Studi Di Roma La Sapienza

Universitaet Des Saarlandes

Universitaet Leipzig

Universitaet ULM

Universitaetsklinikum Essen

Universite de Geneve

University College London

Vivia Biotech S.L.

Weizmann Institute of Science


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.